Active substances
Avibactam + Ceftazidime
- SFDA 1
- US FDA 1
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ZAVICEFTA 2 g/0.5 g Vial | 2,0.5 g,g | Powder for concentrate for solution for infusion · Intravenous use | 10 Vial | SAR 4537.50 | NCE · Prescription | Pfizer Ireland Pharmaceuticals | Valid |
Indications — CHI Daman Drug Formulary
ACUTE PYELONEPHRITIS; BACTERIAL SKIN INFECTIONS - GAS GANGRENE; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; INTRA-ABDOMINAL INFECTIONS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| AVYCAZ | EQ 0.5GM BASE;2GM/VIAL | powder · intravenous | ABBVIE | Prescription | 25 Feb 2015 |
WHO WHO Model List of Essential Medicines (2025)
- 6.2.3. Reserve group antibiotics · complementary
Carbapenem-resistant Pseudomonas aeruginosa; Other carbapenem resistant Enterobacterales; Carbapenem resistant Klebsiella pneumoniae; Carbapenem resistant Escherichia coli
Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.